Inhibikase Therapeutics, Inc. (NYSE:IKT) Director Arvind Kush Purchases 145,000 Shares

Inhibikase Therapeutics, Inc. (NYSE:IKT) Director Arvind Kush bought 145,000 shares of the stock in a transaction dated Monday, October 21st. The stock was purchased at an average price of $1.37 per share, with a total value of $198,650.00. Following the purchase, the director now owns 145,000 shares in the company, valued at $198,650. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Inhibikase Therapeutics Trading Up 15.2 %

Shares of IKT opened at $2.43 on Thursday. The firm has a market cap of $17.53 million, a PE ratio of -0.73 and a beta of 1.32. Inhibikase Therapeutics, Inc. has a 1-year low of $0.80 and a 1-year high of $3.82. The firm has a fifty day simple moving average of $1.39 and a two-hundred day simple moving average of $1.51.

Inhibikase Therapeutics (NYSE:IKT) last announced its earnings results on Wednesday, August 14th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.08). As a group, research analysts forecast that Inhibikase Therapeutics, Inc. will post -2.75 EPS for the current fiscal year.

Institutional Investors Weigh In On Inhibikase Therapeutics

A hedge fund recently bought a new stake in Inhibikase Therapeutics stock. Armistice Capital LLC bought a new stake in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 589,575 shares of the company’s stock, valued at approximately $713,000. Armistice Capital LLC owned 8.17% of Inhibikase Therapeutics at the end of the most recent quarter. 3.81% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright lowered their price objective on Inhibikase Therapeutics from $15.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, October 14th.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.